JP2021513533A5 - - Google Patents

Info

Publication number
JP2021513533A5
JP2021513533A5 JP2020542733A JP2020542733A JP2021513533A5 JP 2021513533 A5 JP2021513533 A5 JP 2021513533A5 JP 2020542733 A JP2020542733 A JP 2020542733A JP 2020542733 A JP2020542733 A JP 2020542733A JP 2021513533 A5 JP2021513533 A5 JP 2021513533A5
Authority
JP
Japan
Prior art keywords
γpantifol
gamma
composition according
polyglutamine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513533A (ja
JP7490240B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017004 external-priority patent/WO2019157148A1/en
Publication of JP2021513533A publication Critical patent/JP2021513533A/ja
Publication of JP2021513533A5 publication Critical patent/JP2021513533A5/ja
Priority to JP2024075778A priority Critical patent/JP7676063B2/ja
Application granted granted Critical
Publication of JP7490240B2 publication Critical patent/JP7490240B2/ja
Priority to JP2025070872A priority patent/JP2025105775A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542733A 2018-02-07 2019-02-07 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用 Active JP7490240B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024075778A JP7676063B2 (ja) 2018-02-07 2024-05-08 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用
JP2025070872A JP2025105775A (ja) 2018-02-07 2025-04-22 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
US201862627733P 2018-02-07 2018-02-07
US201862627732P 2018-02-07 2018-02-07
US62/627,732 2018-02-07
US62/627,733 2018-02-07
US201862630824P 2018-02-14 2018-02-14
US201862630625P 2018-02-14 2018-02-14
US201862630652P 2018-02-14 2018-02-14
US201862630620P 2018-02-14 2018-02-14
US201862630751P 2018-02-14 2018-02-14
US201862630613P 2018-02-14 2018-02-14
US62/630,824 2018-02-14
US62/630,751 2018-02-14
US62/630,652 2018-02-14
US62/630,613 2018-02-14
US62/630,620 2018-02-14
US62/630,625 2018-02-14
US201862636289P 2018-02-28 2018-02-28
US62/636,289 2018-02-28
US201862662372P 2018-04-25 2018-04-25
US62/662,372 2018-04-25
US201862702774P 2018-07-24 2018-07-24
US201862702779P 2018-07-24 2018-07-24
US62/702,774 2018-07-24
US62/702,779 2018-07-24
US201862764951P 2018-08-17 2018-08-17
US201862764945P 2018-08-17 2018-08-17
US62/764,951 2018-08-17
US62/764,945 2018-08-17
PCT/US2019/017004 WO2019157148A1 (en) 2018-02-07 2019-02-07 Gamma polyglutamated antifolates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075778A Division JP7676063B2 (ja) 2018-02-07 2024-05-08 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用

Publications (3)

Publication Number Publication Date
JP2021513533A JP2021513533A (ja) 2021-05-27
JP2021513533A5 true JP2021513533A5 (enExample) 2022-02-16
JP7490240B2 JP7490240B2 (ja) 2024-05-27

Family

ID=67548055

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020542733A Active JP7490240B2 (ja) 2018-02-07 2019-02-07 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用
JP2024075778A Active JP7676063B2 (ja) 2018-02-07 2024-05-08 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用
JP2025070872A Pending JP2025105775A (ja) 2018-02-07 2025-04-22 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024075778A Active JP7676063B2 (ja) 2018-02-07 2024-05-08 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用
JP2025070872A Pending JP2025105775A (ja) 2018-02-07 2025-04-22 ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用

Country Status (5)

Country Link
EP (1) EP3749321A4 (enExample)
JP (3) JP7490240B2 (enExample)
CN (1) CN111936147A (enExample)
CA (1) CA3090505A1 (enExample)
WO (1) WO2019157148A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121177507A (zh) 2016-08-12 2025-12-23 L.E.A.F.控股集团公司 α和γ-D聚谷氨酸化抗叶酸剂及其用途
WO2018031968A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
EP3749314A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
CN111867593A (zh) 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749319A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
WO2019157121A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
WO2019160735A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
JP7462950B2 (ja) 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
US20230000997A1 (en) * 2019-08-06 2023-01-05 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US20020168761A1 (en) * 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
JP2008512490A (ja) * 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
WO2006074416A1 (en) * 2005-01-07 2006-07-13 Health Research Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
US8073630B2 (en) * 2006-08-30 2011-12-06 Exagen Diagnostics, Inc. Pharacogenetic method for prediction of the efficacy of methotrexate monotherapy in recent-onset arthritis
GB2453011B (en) * 2006-12-29 2010-06-23 Tracon Pharmaceuticals Inc Antifolate agent compositions in the treatment of cancer
JP2010516694A (ja) * 2007-01-19 2010-05-20 チェルシー・セラピューティクス，インコーポレイテッド 新規な伝統的葉酸拮抗剤
EP2437596B1 (en) * 2009-06-03 2017-05-03 Ex-Tek, LLC Skin treatment compositions
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
PL226015B1 (pl) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
CN103040748B (zh) 2012-12-18 2014-07-02 海南圣欣医药科技有限公司 一种培美曲塞二钠脂质体注射剂
MA40428A (fr) 2014-08-14 2016-02-18 L E A F Holdings Group Llc Médicament à affinité encapsulé dans un liposome
CN121177507A (zh) 2016-08-12 2025-12-23 L.E.A.F.控股集团公司 α和γ-D聚谷氨酸化抗叶酸剂及其用途
WO2018031968A1 (en) * 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
WO2018031980A1 (en) * 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
ES3062820T3 (en) * 2017-11-08 2026-04-14 L E A F Holdings Group Llc Platinum complexes and uses thereof
JP7491572B2 (ja) * 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
EP3749318A4 (en) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
WO2019157145A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
EP3749314A4 (en) * 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES
WO2019157121A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
CN111867593A (zh) * 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
WO2019157129A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
EP3749319A4 (en) * 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
CA3090389A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12310966B2 (en) * 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
US12350271B2 (en) * 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
WO2019160735A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019160734A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
JP7462950B2 (ja) * 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
CA3090753A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof

Similar Documents

Publication Publication Date Title
JP2021513533A5 (enExample)
JP2021513529A5 (enExample)
JP2021513550A5 (enExample)
JP2021513528A5 (enExample)
JP2021513531A5 (enExample)
JP2021513525A5 (enExample)
JP2021512895A5 (enExample)
JP2021514357A5 (enExample)
JP2017526744A5 (enExample)
JP2019524885A5 (enExample)
JP2025072362A5 (enExample)
JP2019524802A5 (enExample)
Jain et al. Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery
Schulz et al. Beyond the lipid-bilayer: interaction of polymers and nanoparticles with membranes
Xu et al. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo
Suk et al. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier
Liu et al. Formulation of drugs in block copolymer micelles: drug loading and release
AU2011323458B2 (en) Compositions and methods for the delivery of therapeutics
JP6538031B2 (ja) 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療
US20160303047A1 (en) Means for lung specific delivery
JP7803714B2 (ja) 複数のリガンドで機能化されたポリマーソーム
García et al. pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin
Kiss et al. Tuneable surface modification of PLGA nanoparticles carrying new antitubercular drug candidate
US20150125401A1 (en) Small magnetite therapeutics and methods of use thereof
Kiss et al. Protein interaction with a Pluronic-modified poly (lactic acid) Langmuir monolayer